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Abstract
 .Mutations in the gene encoding a recently described lysosomal enzyme, palmitoyl-protein thioesterase PPT , have
 .recently been shown to result in the neurodegenerative disorder, infantile neuronal ceroid lipofuscinosis INCL . Reduced
palmitoyl-protein thioesterase enzyme has been demonstrated previously in INCL brain and immortalized lymphoblasts. In
 .the current paper, we demonstrate that: 1 PPT can be detected by immunoblotting and enzyme activity assays in normal
 .  .human skin fibroblasts; 2 INCL fibroblasts are deficient in PPT activity; 3 I-cell disease fibroblasts show markedly
reduced intracellular levels of PPT but markedly increased levels of PPT in cell culture medium. These data establish that
PPT is transported to lysosomes via the lysosomal enzyme:lysosomal enzyme receptor phosphomannosyl recognition system
under normal physiological conditions and provide the basis for a useful clinical assay for INCL.
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 .Palmitoyl-protein thioesterase PPT was recently
shown to be the defective enzyme responsible for the
neurodegenerative disorder of children, infantile neu-
 . w xronal ceroid lipofuscinosis INCL 1 . This lysoso-
mal storage disorder has an unusually high incidence
 . w xin Finland 1:20 000 2 and is characterized by
global developmental delays, early vision loss,
seizures, sleep disturbances, an isoelectric EEG by 3
w xyears of age, and death between 8–14 years 3 . A
homozygous mutation at nucleotide 364, leading to
an arginine to tryptophan substitution near the puta-
) Corresponding author. Fax: q1 214 6484940; E-mail: Hof-
mann@simmons.swmed.edu
tive active site of the enzyme, accounts for the vast
w xmajority of Finnish cases 1 . The diagnosis is cur-
rently made on the basis of clinical findings and light
and electron microscopic analysis of tissue obtained
w xfrom skin or rectal mucosal biopsy 4 . A characteris-
tic granular autofluorescent storage material is found
w xin brain, skin, chorionic villi and other tissues 5 .
PPT has been recently shown to be a lysosomal
enzyme, thereby confirming the classification of
INCL, based on histologic criteria, as a lysosomal
w xstorage disease 6–8 . In vitro, PPT hydrolyzes long-
chain fatty acids from modified cysteine residues in
w xproteins 9,10 . It is likely that PPT functions in the
cell to metabolize S-acyl proteins in the lysosome, as
w35 xprotein-derived S cysteine-labeled lipid thioesters
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w xaccumulate in INCL cells 11 . Severely reduced PPT
activity has been demonstrated in brain tissue from
INCL patients as compared to normal controls -0.1
.vs. 12.0 pmolrminrmg of soluble brain protein ,
whereas lymphoblasts showed about 40% of normal
activity 0.37 vs. 0.89 pmolrminrmg of crude cell
. w xprotein 1 . Lysosomal PPT activity is absent from
INCL lymphoblasts; the remaining low level of PPT
activity in these cells resides in non-lysosomal sub-
w xcellular fractions 12 .
When recombinant PPT is overexpressed in a tran-
sient transfection system, the enzyme is phosphory-
lated on mannose residues and transported to lyso-
somes through the mannose 6-phosphate receptor
w xpathway 6 . This provides strong, yet indirect, evi-
dence that PPT is directed to lysosomes through this
pathway under physiological conditions. To examine
the targeting of PPT under conditions of normal
expression, we examined PPT activity and immuno-
 .reactivity in fibroblasts of patients with I inclusion -
cell disease, a disorder of lysosomal enzyme targeting
through the mannose 6-phosphate receptor pathway.
Patients with this disease have a defect in UDP-N-
acetylglucosamine:glycoprotein N-acetylgluco-
saminylphosphotransferase, the enzyme responsible
for adding N-acetylglucosamine 1-phosphate to spe-
w xcific mannose residues of lysosomal enzymes 13 .
Subsequent post-translational enzymatic processing
results in the removal of the N-acetylglucosamine
residues, resulting in the exposure of mannose 6-
phosphate moieties on the lysosomal enzymes. These
mannose 6-phosphate moieties, in turn, enable an
interaction between the newly synthesized lysosomal
enzymes and their receptor, resulting in the intra-
cellular transport of these enzymes to lysosomes.
Fibroblasts from I-cell disease patients synthesize
lysosomal enzymes that lack the mannose 6-phos-
phate recognition signal and are therefore not routed
w xto lysosomes in these cells 14 . Rather, the lysoso-
mal enzymes are secreted and found at elevated
w xlevels in the culture medium and body fluids 15 .
In the current study, we analyzed two independent
INCL fibroblast cultures for PPT enzyme activity and
immunoreactivity, and also surveyed fibroblasts de-
rived from a panel of patients with a variety of
lysosomal storage diseases, including I-cell disease.
We demonstrate that PPT is undetectable by
immunoblotting and shows severely reduced activity
in fibroblasts from two unrelated INCL patients. We
also show that PPT is undetectable in fibroblasts
from a patient with I-cell disease but that the enzyme
appears at elevated levels in the culture medium,
indicating that PPT, like many but not all lysosomal
enzymes, is transported to lysosomes after its synthe-
sis via a phosphomannosyl receptor mechanism.
Fibroblast cultures were derived from patients with
lysosomal storage disorders at the Shriver Center
 .Waltham, MA . INCL fibroblasts were obtained from
two unrelated U.S. patients without known Finnish
ancestry. One of these cultures was obtained through
Coriell formerly, ATCC, NIGMS Mutant Cell
.Repository No. GM09405 . Cells were maintained in
monolayer culture in Dulbecco’s modified Eagles’
 .  .medium high glucose supplemented with 15% vrv
heat-inactivated fetal bovine serum, 1% L-glutamine,
100 unitsrml penicillin, 100 mgrml streptomycin,
and 0.25 mgrml amphotericin B. Whole cell lysates
were prepared from confluent dishes of cells by
harvesting cells in a buffer containing 50 mM Tris-
HCl, pH 7.0, 150 mM NaCl, 2 mM EDTA, 1 mgrml
pepstatin A, and 2 mgrml leupeptin and sonicating
briefly on ice.
Whole cell lysates were analyzed by immuno-
blotting using anti-human PPT antibodies that were
raised in rabbits using full-length recombinant human
PPT as antigen in a manner similar to that previously
described for the preparation of anti-bovine PPT anti-
w xbodies 6 . An IgG fraction was prepared from preim-
mune and immune sera by protein A Sepharose CL-
 .4B chromatography Pharmacia Biotech Inc. . Crude
 .cell lysates 25 mg of total protein were elec-
trophoresed on 12% SDS-polyacrylamide gels, trans-
ferred to nitrocellulose, and analyzed by immuno-
blotting using IgG purified anti-human PPT antibod-
 . w xies 1.5 mgrml as described previously 6 .
To analyze PPT protein in the medium from fi-
broblast cultures, a partial purification was carried
out to enrich for PPT prior to immunoblotting. Cul-
 .ture medium 4 ml was harvested from confluent
dishes of cells and adjusted to 2.5 M NaCl, 30 mM
Tris-HCl pH 7.0, and 0.2 mM phenylmethanesulfonyl
fluoride. Samples were incubated with 400 ml of a
50:50 slurry of phenyl Sepharose CL-4B Pharmacia
.Biotech in 2.5 M NaCl for 3 h on a laboratory
rotator at 48C. The resin-containing samples were
poured into 10 ml Poly-Prep chromatography columns
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 .Bio-Rad Laboratories and allowed to drain by grav-
ity. The resin was washed with 10 ml high salt buffer
 .2.5 M NaCl, 30 mM Tris-HCl pH 7.0 and 40 ml
 .low salt buffer 5 mM Tris-HCl pH 7.0 . PPT was
eluted from the resin with 2.5 ml elution buffer 75%
 ..ethylene glycol, 25% 5mM Tris-HCl pH 7.0 vrv .
Samples were diluted with 4 volumes 50 mM Tris-
HCl, pH 7.0, 150 mM NaCl, 2 mM EDTA, 0.2%
n-octylglucoside and concentrated to 70 ml using
 .  .Centricon-30 concentrators Amicon . Samples 7 ml
were subjected to electrophoresis on a 12% poly-
acrylamide gel, transferred to nitrocellulose, and ana-
lyzed by immunoblotting as described for the crude
cell lysates.
Fig. 1A shows an immunoblot of fibroblast
whole-cell extracts from patients with a variety of
lysosomal storage disorders. In normal fibroblasts
 .lane 1 , PPT appears as a doublet at molecular
masses of 36.5 K and 34 K. I-cell disease fibroblasts
 .lane 2 show no detectable PPT. Since PPT has been
shown to be a lysosomal enzyme, this result is consis-
tent with PPT lacking the mannose 6-phosphate
recognition signal, with subsequent failure to target
PPT to lysosomes in these cells. Patients with galac-
 .tosialidosis lane 3 show a PPT doublet with abnor-
mally slow electrophoretic migration. These patients
have a defect in oligosaccharide processing due to a
w xdeficiency in the lysosomal protective protein 16
that results in a secondary deficiency of lysosomal
w xb-galactosidase and neuraminidase activities 17 , and
abnormal electrophoretic migration of a number of
lysosomal proteins. Fibroblasts from a U.S. INCL
 .patient lane 9 showed an absence of detectable
immunoreactivity. Fibroblasts from a second INCL
 .patient yielded the same results data not shown .
PPT immunoreactivity was normal in fibroblasts from
patients with other lysosomal storage diseases lanes
.4–8 .
Fig. 1B shows an analysis of PPT in the culture
medium of the same fibroblast lines shown in Fig.
1A. PPT was readily and reproducibly detected in
culture medium of fibroblasts from the I-cell disease
 .patient lane 2 . The secreted PPT appeared as a
doublet of molecular masses of 39 K and 37 K. The
slower migration of secreted forms of PPT is consis-
tent with further oligosaccharide processing of PPT
in the Golgi after failure to phosphorylate mannose
w xresidues 18 . Traces of PPT immunoreactivity were
Fig. 1. Immunoblot analysis of PPT in fibroblasts and culture medium. A. Whole cell extracts were subjected to electrophoresis in 12%
SDS-polyacrylamide gels and transferred to nitrocellulose filters. Immunoreactive bands were visualized by incubation with polyclonal
rabbit anti-human PPT antibodies and enhanced chemiluminescence. PPT appears as a doublet of molecular masses 34 K and 36.5 K.
 .Bands observed at 40 K and 58 K were also seen with preimmune IgG data not shown . B. Fibroblast culture medium was treated as
described in the text and subjected to electrophoresis and immunoblotting. PPT from the culture medium appears as a doublet of
molecular masses 37 K and 39 K. Lane 1: normal fibroblasts. Lane 2: I-cell disease. Lane 3: galactosialidosis. Lane 4: Sandhoff disease.
Lane 5: metachromatic leukodystrophy. Lane 6: Hurler disease. Lane 7: Krabbe disease. Lane 8: Pompe disease. Lane 9: INCL. This
experiment was performed three times with similar results.
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Fig. 2. PPT activity is decreased in fibroblasts from INCL and
I-cell disease patients, but not in fibroblasts from patients with
other lysosomal storage disorders. Whole cell extracts were pre-
pared and assayed for PPT activity as described in the text. Lanes
are exactly as described in Fig. 1. Values represent the mean"
standard error for three determinations performed on each cell
line.
occasionally found in culture medium from some
 .fibroblast samples see, for instance, lane 7 but these
findings were inconsistent.
We were unable to detect PPT in serum from
I-cell patients by immunoblotting or enzyme assay.
The explanation for this may be related to a marked
inhibition of PPT activity observed when purified
recombinant PPT is added to normal serum data not
.shown .
Fig. 2 shows an analysis of PPT enzyme activity in
whole cell lysates from the fibroblasts shown in Fig.
w3 x1. The assay measures the removal of H palmitate
w3 xfrom a palmitoylated protein H palmitate-labeled
. w xH-Ras 9 . Cell extracts were preincubated in
 .phenylmethanesulfonyl fluoride PMSF to inhibit
background PMSF-sensitive thioesterase activity; PPT
activity has previously been shown to be resistant to
w xPMSF 9 . In keeping with the results of Fig. 1, PPT
activity is significantly reduced in cells from patients
 .  .with I-cell disease lane 2 and INCL lane 9 reflect-
ing the absence of PPT enzyme activity. Fibroblasts
from the second INCL patient also showed negligible
 .activity data not shown . There were normal levels
of PPT activity in cells from patients with other
 .lysosomal storage diseases lanes 3–8 . Cells from
 .the patient with galactosialidosis lane 3 show nor-
mal PPT activity, indicating that the abnormal pro-
cessing of the oligosaccharides on PPT in these cells
did not affect the catalytic activity of PPT measured
in the in vitro assay.
In conclusion, the data presented here indicate that
PPT can be demonstrated by both enzyme activity
and immunoassays in normal cultured skin fibrob-
lasts. In addition, PPT deficiency can be demon-
strated in fibroblast cell lines from patients with
INCL. In the two particular INCL lines reported here,
PPT was undetectable both by activity and immuno-
blotting assays. These assays may have advantages
over electron microscopic assays for INCL and should
facilitate the identification of other PPT deficient
patients having phenotypes different from classic
INCL.
In addition, the data presented here provide direct
support that PPT is routed to lysosomes via a man-
nose 6-phosphate receptor pathway, in a physiologic
setting not involving overexpression of the protein in
a heterologous cell line.
It is possible that PPT deficiency contributes, at
least in part, to the accumulation of storage material
in I-cell disease as well as in INCL. Further charac-
terization of the storage material in both lysosomal
storage diseases may help to address this possibility.
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